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Abstract
Background: Prostate cancer is the second most common malignancy in men in the
world, and radiotherapy is used as a standard treatment modality for this cancer.
Although this treatment modality effectively kills prostate cancerous cells, it
unavoidably irradiates the organs/tissues that are away from the treatment site. In
this regard, radiation‐induced testicular toxicities following prostate radiotherapy can
affect sexual function, reproduction, and quality of life in cancer survivors. This
review summarizes the available data on testicular exposure to radiation during
prostate radiotherapy and the consequences on testicular function.
Methods: To illuminate the radiation‐induced testicular toxicities following prostate
radiotherapy, a systematic search was conducted based on the Preferred Reporting
Items for Systematic Reviews and Meta‐Analyses guideline in PubMed, Web of
Science, Scopus, Embase, and clinical trials electronic databases up to September
2018. According to a set of prespecified inclusion and exclusion criteria, 31 eligible
articles providing data on testicular function following radiotherapy in patients with
prostate cancer were included in the study.
Results: According to the different radiotherapeutic techniques used for prostate cancer
treatment, the total tumor dose and scattered testicular dose values were ranging from
36.25 to 78.00Gy and 0.06 to 6.48Gy, respectively. Luteinizing hormone and follicle‐
stimulating hormone levels after prostate radiotherapy were signiﬁcantly higher in
comparison with the pretreatment levels. Around 60% of the studies showed that
testosterone levels after prostate radiotherapy were signiﬁcantly lower than the
pretreatment levels. Furthermore, erectile dysfunction (ED), as an adverse side effect
resulting from prostate radiotherapy, was reported and this complication is signiﬁcantly
correlated with lower satisfaction with sexual life. Testicular atrophy following prostate
radiotherapy has also been observed and its frequency in patients with prior prostate
radiotherapy is 2.5 times more than that in the patients without prior radiotherapy.
Conclusion: The data revealed that the scattered dose to testicular tissues during
prostate radiotherapy can lead to testicular atrophy, variation of the male sex
hormones, and quality of sexual life.
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1 | INTRODUCTION
Prostate cancer is the second most common malignancy in men in the
world and the first most common malignancy in European and
American men; as 1.1 million men suffered from this malignancy in
the world, about 70% in developing countries (Bray, Lortet‐Tieulent,
Ferlay, Forman, & Auvinen, 2010; Farhood, Geraily, & Alizadeh, 2018;
Ferlay et al., 2015; Sadjadi et al., 2007). Treatment modalities for
prostate cancer include radical prostatectomy, radiotherapy, and
hormonal therapy (van der Wielen, van Putten, & Incrocci, 2007).
External beam radiotherapy (EBRT) has been accepted as a standard
treatment modality for prostate cancer, which can be carried out as
conventional radiotherapy, three‐dimensional conformal radiation
therapy (3D‐CRT), intensity‐modulated radiation therapy (IMRT), and
ion beam radiotherapy, and so forth (Boehmer, Badakhshi, Kuschke,
Bohsung, & Budach, 2005; Yonai, Matsufuji, & Akahane, 2018).
In radiotherapy, the main purpose is covering the treatment
volume with sufficient radiation dose whereas minimizing the
radiation dose received by the surrounding normal tissues (Farhood,
Geraily, & Abtahi, 2018). Nevertheless, this treatment modality
unavoidably irradiates the organs/tissues that are away from the
treatment site and radiation doses received to these organs/tissues
can lead to adverse side effects (Bagheri, Rabie Mahdavi, Shekarchi,
Manouchehri, & Farhood, 2018).
Sexual and reproductive complications following prostate radio-
therapy are an important consideration owing to the radiosensitive
nature of testicular tissues and their close proximity to target
radiation volume (Oermann et al., 2011; Yau et al., 2009). These
treatment‐related toxicities affect sexual function, quality of life, and
reproduction of cancer survivors (Nicholas et al., 2017). Testicular
tissues have two different compartments that are particularly
affected by radiation damage. First, seminiferous tubules, which are
responsible for spermatogenesis and considered as radiosensitive
tissues; as radiation‐induced damage to these tubules may lead to
permanent infertility. Second, Leydig cells, which secrete testoster-
one and are relatively resistant to radiation; as low level of
testosterone following radiation may cause decreased libido and
sexual function, altered personality, reduced stamina or depression
(Ahmadloo et al., 2010; Bruheim et al., 2008; Nicholas et al., 2017).
Furthermore, the testicular function is regulated by luteinizing
hormone (LH) and follicle‐stimulating hormone (FSH) on the Leydig
cells and Sertoli cells, respectively. LH through its interaction with
Leydig cells (under negative feedback) controls testosterone produc-
tion; as radiation‐induced damage to the Leydig cells will prevent
testosterone production and lead to a compensatory increment in LH
levels. The Sertoli cells are located inside the seminiferous tubules
and are responsible for spermatogenesis; therefore, radiation‐
induced damage to these cells can impair sperm production and
thereby increment of the pituitary release of FSH (Dueland, Grønlie
Guren, Rune Olsen, Poulsen, & Magne Tveit, 2003; Hermann
et al., 2005).
To the best of our knowledge, the current study is the first
systematic review on the radiation‐induced testicular toxicities
following prostate radiotherapy. Therefore, the aim of this review
is to summarize data regarding the effect of prostate radiotherapy on
the testicular function.
2 | METHODS
2.1 | Search strategy
Preferred Reporting Items for Systematic Reviews and Meta‐
Analyses guidelines was used to design this systematic review
(Moher, Liberati, Tetzlaff, & Altman, 2009). The literature search was
performed to evaluate all relevant studies on the electronic
databases of Web of Science, PubMed, EMBASE, Scopus, and clinical
trials by two study investigators (Bagher Farhood and Hamed Haghi–
Aminjan), independently. The search strategy used in the current
study was according to the following keywords in the title and
abstract: (Radiation OR Radiotherapy) AND (Prostate neoplasms OR
Prostate cancer OR Prostate malignancy) AND (Testes OR Testis
OR Testicular OR Spermatozoa OR Germ cells OR Leydig cells OR
Gonadal hormones OR Seminiferous tubules OR Sex hormones OR
Follicle stimulating hormone OR FSH OR Luteinizing hormone OR LH
OR Testosterone OR Sperm OR Hypogonadism).
2.2 | Study selection
The current systematic review included all published articles up to
September 2018. In this study, original articles with the following
inclusion criteria were included: (a) relevant studies with aforemen-
tioned keywords; (b) studies with sufficient data; (c) studies with
physics contributions; (d) studies with clinical data; (e) unpublished
clinical trials with results posted, and (f) studies in English language.
Furthermore, exclusion criteria were: (a) articles with unrelated
information; (b) articles with insufficient information (d) review
articles, (e) editorials, and (f) letter to the editor.
2.3 | Data extraction
Each data of eligible paper was extracted by BF according to a form
and checked by HHA. When there was a discrepancy between these
two investigators, it was resolved by referring back to the article. Our
extraction form includes the following information (a) author name
and year of publication; (b) type of study (clinical investigation or
physics contribution); (c) therapeutic technique type; (d) total
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radiation dose to target volume; (e) radiation dose received to
testicular tissues; (f) testicular complication induced by prostate
radiotherapy.
3 | RESULTS
3.1 | Literature search
Figure 1 shows the process of study selection.
Our initial search on above‐mentioned databases up to September
2018 obtained 8,439 articles. After screening the articles, 8,191 of
them were excluded by evaluating their titles and abstracts and
248 articles were qualified for assessment of their full‐text. Afterward,
studies in consistent with the exclusion criteria or the articles with
missing data were excluded. Eventually, 31 remaining studies were
contained in this systematic review. Table 1 represents a summary of
the obtained data and characteristics of the eligible articles included
in this.
3.2 | Radiation‐induced testicular toxicities
following radiotherapy for prostate cancer
In this section, the relevant studies are presented in two categories:
(a) physics contributions and (b) clinical investigations.
3.2.1 | Studies of Physics contributions
Amies, Mameghan, Rose, & Fisher (1995) measured dose values of
unshielded‐testicular tissues during conventional radiotherapy with
18 MV photon energy in patients with localized prostate cancer by
thermoluminescence detector (TLD). The total dose prescribed to the
patients ranged from 60 to 66Gy, and the mean testicular dose
values in the patients ranged from 154.3 to 216.8 cGy. Moreover,
they stated that distance between the testicular tissues and lower
border of the treatment field is one of the most important factors
influencing the dose received by these tissues (Amies et al., 1995).
Budgell, Cowan, & Hounsell (2001) measured scattered dose to
the testicular tissues in abdominopelvic radiotherapy. They repre-
sented that the dose values received by these tissues during prostate
radiotherapy range from 0.2 to 1.3 Gy for 60 Gy prostate treatments
(i.e., 0.4–2.2% of prescribed dose; Budgell et al., 2001).
In a study by Boehmer et al. (2005), radiation dose values
received by unshielded‐testicular tissues of 20 randomly selected
patients with prostate cancer during 3D‐CRT with 20‐MV photon
energy were measured by online thermoluminescence dosimetry. For
all patients, the total dose delivered to planning target volume was
72Gy during 40 treatment fractions. Their results demonstrated that
the dose values received by testicular tissues during total treatment
are ranging from 36 to 557 cGy (with a mean dose of 196 ± 145 cGy).
Finally, they concluded that the scattered testicular dose values
during EBRT of patients with prostate cancer can lead to an
impairment of the reproductive function of testicles (Boehmer
et al., 2005).
Deng, Chen, & Nath () evaluated testicular dose resulting from
kilovoltage cone beam computed tomography (kVCBCT) on image‐
guided radiotherapy (IGRT) of prostate cancer by Monte Carlo
simulation. Their data showed that kVCBCT can increase the
testicular dose to almost 1.2 Gy, up by 330% in comparison with
regular IMRT technique without kVCBCT. Furthermore, they
revealed that the reduction of the kVCBCT field size from 0.30 to
0.15m in superior–inferior direction would decrease the dose value
received by testes from 4.2 to 0.4 cGy per scan (Deng et al.,). In
another study, they reported that with increasing photon beam
energy of CBCT scan from 60 to 125 kV, and kVCBCT‐contributed
testicular dose increases exponentially. Finally, they stated that
during a regular course of prostate IGRT with 79.2 Gy total dose, the
testicular dose contributing from kVCBCT would be about 1.3 Gy
(Deng et al., 2012).
King, Maxim, Hsu, & Kapp (2010) assessed and analyzed the
contribution of different sources yielding to incidental dose to
testicular tissues during image‐guided IMRT for patients with
localized prostate cancer. Dose prescriptions to prostate and pelvic
nodal field were 78 and 50 Gy, respectively. Their findings
demonstrated that for 6 and 15 MV photon energies, mean
testicular dose receiving from pelvic nodal ﬁelds are 172 and
220 cGy and for prostate‐only ﬁelds are 68 and 93 cGy, respec-
tively. The mean testicular dose resulting from daily portal MV
image guidance was 366 cGy. Also, mean neutron dose received by
testicular tissues from 15‐MV photon energies were 60 and 31 cGy
for pelvic and prostate‐only ﬁelds, respectively. In total, they
reported that worst case and best case scenarios can potentially
deliver cumulative mean testicular dose values of 630 and 84 cGy,
respectively (King et al., 2010).
Banaee, Nedaie, Esmati, Nosrati, & Jamali (2014) investigated
dose values absorbed by testicular tissues in prostate radiotherapy
with 18‐MV photon energies. A total dose of 50 Gy was delivered to
the patients and dose values absorbed by the testes were measured
F IGURE 1 Flowchart of the study selection process [Color figure
can be viewed at wileyonlinelibrary.com]
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by TLDs in the absence and presence of testicular shield. Their
findings showed that mean testicular dose values in presence and
absence of testicular shield are 7.37 ± 0.93 and 14.1 ± 5.09, respec-
tively. Finally, they concluded that the use of the testicular shield can
make a 40–70% reduction in dose absorbed by the testes (Banaee
et al., 2014).
Onal, Arslan, Dolek, & Efe (2016) assessed incidental testicular
dose values during prostate radiotherapy with IMRT and VMAT
techniques at various photon energies. In this study, the total
prescribed dose to planning target volume was 78 Gy. In the IMRT
plans, the mean scattered testes dose values in the phantom
measurements (by metal‐oxide‐semiconductor ﬁeld effect transistor
detector) were 0.995 ± 0.172, 1.187 ± 0.164, and 1.939 ± 0.145Gy at
6, 10, and 15 MV photon energies, respectively, and corresponding
dose values in the VMAT plans were 0.904 ± 0.163, 1.036 ± 0.164,
and 1.393 ± 0.146 Gy. They concluded that lower photon energy and
the IMRT plans lead to lower incidental testes dose values compared
with higher photon energy and the VMAT plans (Onal et al., 2016).
Kowalik et al. (2017) measured photon and neutron dose values
received by organs at risks during 3D‐CRT, IMRT, and tomotherapy in
an anthropomorphic phantom by TLDs. For each technique, total dose
prescription to planning target volume was 76Gy. In this study,
the photon dose values delivered to testes for 3D‐CRT, IMRT,
and tomotherapy techniques were 4.38 ± 0.017, 6.48 ± 0.013, and
4.39 ± 0.020Gy, respectively. In addition, mean neutron dose resulting
from 20‐MV photon beams in IMRT technique was 5.777 ± 0.127mSv/
Gy; as this effective dose did not change signiﬁcantly over the whole
body of the phantom. Finally, they represented that in tomotherapy
technique, all organs at risks outside treatment ﬁeld are well‐spared as
well as neutron dose resulting from the high‐energy photon beam
constitutes a considerable contribution (0.5%) of the dose prescription
(Kowalik et al., 2017).
Yonai et al. (2018) estimated absorbed dose and dose equivalent
to out‐of‐ﬁeld organs (by Monte Carlo simulation) during carbon ion
radiotherapy for treatment of prostate cancer. Their findings
revealed, that the dose value reduces with distance from the target
value and absorbed dose and dose equivalent values in the testes
(which was located at the distance of 11.3 cm from the center of
prostate mass) were 56.7 and 116mSv, respectively. Furthermore,
they reported that the organ dose equivalent in the testes per
treatment dose is less than those either in brachytherapy with an
Ir‐192 source or in 6 MV IMRT (Yonai et al., 2018).
3.2.2 | Studies of clinical investigations
Tomić, Bergman, Bamber, Littbranb, & Löfroth (1983) analyzed male
sex hormones of patients with prostate cancer after EBRT. Mean
total tumor dose was 63.5 Gy, and absorbed dose values to the
testicular tissues were about 1 to more than 10 Gy. Their results
showed that the testosterone concentrations after treatment
significantly are lower prior treatment. Also, LH and FSH concentra-
tions after treatment significantly were higher prior treatment. The
highest testosterone variation was found 1 week after the treatment
in the patients who the testicular tissues had been received more
than 10 Gy (Tomić et al., 1983).
Grigsby and Perez determined serum levels of LH, FSH,
testosterone, and dihydrotestosterone hormones in patients with
prostate cancer treated with EBRT. In this study, a total scattered
dose to testicular tissues was ranging from 4.50 to 6.00 Gy. The
findings related to before treatment and up to 2 years after
completing the treatment we demonstrated that testosterone levels
do not change but dihydrotestosterone levels decrease slightly. In
addition, LH and FSH levels increased significantly (Grigsby &
Perez, 1986).
Zagars and Pollack assessed testosterone levels after prostate
radiotherapy. For a total dose of 68 Gy, the mean testicular dose was
2.07 Gy. Mean pre‐ and 3‐month posttreatment testosterone levels
were 400 and 356 ng/dl, respectively; as this decrease was significant
than the pretreatment value. In conclusion, they stated that the
decreased testosterone level after radiotherapy is very small
quantitatively and it can be clinically insignificant (Zagars & Pollack,
1997).
Daniell and Tam evaluated the frequency of testicular atrophy in
orchiectomy specimens obtained from males with prostate radio-
therapy. Their results showed that the patients with prior prostate
radiotherapy have testicular atrophy more frequently than males
without prior radiotherapy (71% vs. 28%). In addition, they reported
that the considerable testicular atrophy happens with similar
frequency in specimens from both older and younger males, and it
is more common in specimens with 3 years after radiotherapy than
those obtained after longer posttreatment (89% vs. 53%; Daniell &
Tam, 1998). In another study, Daniell (1998) reported that the
testicular atrophy resulting from prostate radiotherapy is associated
with poor prognosis. In another work, Daniell et al. (1998)
investigated testicular damage resulting from prostate EBRT and
conﬁrmed the presence of hypogonadism in males with prior EBRT.
Furthermore, they reported that high variations in the degree of
hypogonadism among the patients may be because of differences in
their age and anatomy.
Pickles et al. investigated testosterone level of patients with
prostate cancer after EBRT. For total doses of 52.5–70 Gy, mean
testicular dose was 2.2 Gy (1.2–5.4 Gy). Their findings revealed that
at a median nadir time of 6 months, testosterone levels decline to an
average of 83% of baseline. In conclusion, they stated that temporary
testosterone levels decrease following prostate radiotherapy, with-
out impact on subsequent tumor outcomes (26).
van der Wielen et al. (2007) assessed erectile and sexual function
of patients during prostate 3D‐CRT. Their results demonstrated that
after 1, 2, and 3 years of treatment, 27, 36, and 38% of the patients
have developed erectile dysfunction (ED). Furthermore, there was a
signiﬁcant correlation between lower satisfaction with sexual life and
development of ED (van der Wielen et al., 2007).
Kerns et al. (2010) investigated single nucleotide polymorphisms
(SNPs) associated with ED, as an adverse effect resulting from EBRT,
among African–American patients with prostate cancer. Their results
showed that SNP rs2268363 is significantly associated with ED. This
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SNP is located within the follicle‐stimulating hormone receptor gene,
whose encoded product has a role in the development and function
of male gonads (Kerns et al., 2010).
Oermann et al. (2011) evaluated the incidence of hypogonadism
following SBRT for patients with prostate cancer. The patients were
treated with a 36.25 Gy total dose (in five fractions), and mean
scatter dose received to testicular tissues was 2.1 Gy. By comparing
pre‐ and posttreatment total testosterone levels, the results showed
that at 1 year after treatment completion, testosterone levels of the
patients slowly decrease and these testosterone levels were
significantly less than the pretreatment values. Furthermore, they
reported that there is no increment in biochemical hypogonadism at
1 year after treatment. The findings related to sexual dysfunction of
the patient revealed that average expanded prostate cancer index
composite sexual and hormonal scores are not significantly varied by
1 year after treatment (Oermann et al., 2011).
Golfam, Samant, Eapen, & Malone (2012) evaluated testosterone
changes in patients with localized prostate cancer treated by 3D‐
CRT. Their findings revealed that there is no significant decrease in
serum testosterone level of the patients during 18 months after
radiotherapy.
Ishiyama et al. (2012) investigated the relationship between
testosterone level and dose absorbed by testes in prostate cancer
patients treated with IMRT. In this study, a mean total dose of 76 Gy
was delivered to the prostate and the mean total dose absorbed by
the testes was 5.3 Gy. Also, the mean pretreatment testosterone
level of the patients was 310 ng/dl; as the mean testosterone levels
were significantly reduced at 12, 24, 30, 36 months after IMRT
(Ishiyama et al., 2012).
Nichols et al. (2012) evaluated testosterone levels of patients
with prostate cancer in pre‐ and posttreatment with conformal
proton radiotherapy. The median pretreatment testosterone level of
patients was 357.9 ng/dL and their median posttreatment testoster-
one values were 375.5, 369.9, 348.7, 353.4, and 340.9 ng/dl at
treatment completion, 6, 12, 18, and 24 months after treatment,
respectively. In conclusion, they reported that the treatment of
prostate cancer with conformal proton therapy does not result in a
signiﬁcant effect on testosterone levels of patients during 2 years
after radiotherapy (Nichols et al., 2012).
Kil et al. (2013) assessed testosterone levels of patients with
prostate cancer in pre‐ and posttreatment with proton radiotherapy.
The median testosterone level before treatment was 367.7 ng/dl, and
the median changes in testosterone levels after treatment comple-
tion, 6 and 12 months after treatment were −3.0, −6.0, and
+5.0 ng/dl, respectively. Statistically, these changes were not sign-
iﬁcant. In conclusion, they stated that patients with prostate cancer
treated with proton radiotherapy are not confronted with testoster-
one suppression (Kil et al., 2013).
Markovina et al. (2014) investigated testosterone level and
incidence of biochemical hypogonadism in patients with prostate
cancer treated with IMRT. A significant decrease in testosterone
levels at 6 months after treatment completion was observed, but
testosterone levels returned to baseline levels by 1 year after IMRT.
Moreover, none of the increase in biochemical hypogonadism was
seen after IMRT (Markovina et al., 2014).
Kitahara, Kobayashi, Yano, Kusuda, & Komatsu (2014) assessed
changes in male sex hormone levels following prostate 3D‐CRT. The
obtained results showed that radiotherapy does not change serum
testosterone level, but it significantly increases both LH and FSH in
serum level (Kitahara et al., 2014).
Planas et al. (2016) measured pre‐ and posttreatment serum
levels of LH, FSH, estradiol, total testosterone, and free testoster-
one of patients with prostate cancer treated by IMRT. In this
study, the patients were treated with a 75 Gy total dose, and mean
scatter dose received to testicular tissues was 0.47 Gy. Their
results showed that at 3 months after treatment completion, LH
and FSH levels are signiﬁcantly more than the baseline levels
whereas total testosterone and free testosterone levels are
signiﬁcantly lower. At 12 months after treatment completion,
FSH levels were signiﬁcantly more than the baseline levels
whereas total testosterone levels remained significantly lower.
There were no signiﬁcant changes related to other hormonal levels
at any time after treatment (Planas et al., 2016).
Lehto, Tenhola, Taari, & Aromaa (2017) investigated the
adverse effects of prostate EBRT in large population‐based
samples (523 patients). In this study, 79% of the patients reported
sexual dysfunction such as loss of libido/sexual desire, impotence,
or the loss of both potency and desire after EBRT. Also, 11% of the
patients reported permanent sexual difficulties after EBRT
(Lehto et al., 2017).
Pompe et al. (2017) evaluated the effect of prostate EBRT on
testosterone kinetics of a large series of patients with cancer.
About 75% of the patients revealed a considerable decrease in the
testosterone level, and median time to ﬁrst decrement was
6.4 months after EBRT. More than 60% of the patients with
testosterone decrement recovered to at least 90% of baseline
levels during 6 months of the nadir. Moreover, their findings
showed that there is a lower chance of testosterone recovery for
increased body mass index, advanced age, lower nadir level, and
higher baseline testosterone level (Pompe et al., 2017).
Ataei, Leventouri, and Pella (2017) investigated the effect of
prostate radiotherapy on quality of sperm during and after
treatment. Their results demonstrated that there are no variations
in the quality of sperm during radiotherapy, but the findings later
revealed 1–3% reduce in sperm’s life span and 2–3% reduce in the
quality of sperm (Ataei et al., 2017).
Zelefsky evaluated male sexual function and ED of patients with
prostate cancer treated by radiotherapy (NCT00142506). The Interna-
tional Index of Erectile Function (IIEF) was used for the assessment of
male sexual function and diagnostic investigation of ED severity. There
are five domains of the IIEF: erectile function, orgasmic function, sexual
desire, intercourse satisfaction, and overall satisfaction. A score of 0–5
was awarded to each question of the IIEF. Total IIEF scores range from
0 to 75. Lower scores indicate severe ED (0 = severe ED), whereas
higher scores indicate less ED (75 = no ED). In this report, median IIEF
scores in the baseline, 6, 12, and 24 months after radiotherapy were 64
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(56.75–69.00), 58 (35.00–64.00), 51 (34.50–63.50), and 54.50
(29.75–64.75), respectively (NCT00142506).
4 | DISCUSSION
In the current study, the data related to clinical studies, which
evaluated testicular toxicities resulting from prostate cancer radio-
therapy were summarized. Furthermore, the Physics contributions
regarding measurement/estimation of dose values received by
testicular tissues during prostate radiotherapy were studied. The
dosimetric data and clinical outcomes of the above‐mentioned
eligible studies are represented in Table 1.
Referring to Table 1, it is found that according to the various
radiotherapeutic techniques, the total dose to planning target volume
ranges from 36.25 to 78.00 Gy. Furthermore, testicular dose values
resulting from prostate EBRT ranged from 0.06 to 6.48 Gy. There are
several factors, which can affect scattered dose values to testes
during prostate radiotherapy and their subsequent adverse side
effects including beam and energy type used for prostate radio-
therapy, different treatment techniques used, distance between the
testicular tissues and lower border of treatment field, energy beam
and field size of KVCBCT, and absence/presence of testicular shield.
The findings of the current study revealed that the prostate
radiotherapy can lead to changes in testicular function following
which will be explained in detail in each case.
4.1 | Effects of prostate radiotherapy on
spermatogenesis
Spermatogenesis starts in the testicular tissues during early puberty.
It includes the whole development course, from spermatogonia to
sperm. This course happens in the seminiferous tubules and
comprises the various stages of differentiation of Sertoli cells and
germ cells (Harel, Ferme, & Poirot, 2011). The seminiferous tubules
are radiosensitive and dose values as low as 0.1 Gy may result in the
temporary arrest of spermatogenesis (Pryzant, Meistrich, Wilson,
Brown, & McLaughlin, 1993).
It was reported that there are no significant changes in sperm
production and its quality 2–3 years after prostate radiotherapy
(Ataei et al., 2017). According to a study in a population of healthy
prisoners, it was shown that dose values of 4–6 Gy led to a signiﬁcant
decrease in the numbers of spermatozoa (Rowley, Leach, Warner, &
Heller, 1974). In another study, in patients irradiated for Hodgkin’s
disease, it was revealed that a testicular dose between 0.2–0.7 Gy
leads to a decrease in sperm concentration (Kinsella et al., 1989). In
general, a radiation‐induced permanent azo‐ospermia may happen
with a total testicular dose of about 1.2–1.4 Gy during a fractionated
radiotherapy (Buchli, Martling, Arver, & Holm, 2011). Radiation‐
induced azo‐ospermia has been observed at dose values of 0.65 and
4–6Gy during 9–18 months and 5 years to permanently, respectively
(Patel & Rossi, 2014). Furthermore, a high risk of permanent azo‐
ospermia has been reported for fractionated‐testicular dose values
>1.5 Gy (Piroth, Hensley, Wannenmacher, & Zierhut, 2003). Radia-
tion may also lead to DNA fragmentation in sperm and subsequently
a negative effect on future fertility (González‐Marín, Gosálvez, &
Roy, 2012).
4.2 | Effects of prostate radiotherapy on male sex
hormones
LH and FSH are pituitary hormones that regulate testicular function.
Moreover, testosterone is produced mainly in Leydig cells and the
number of these cells is in turn controlled by LH and FSH. The
amount of testosterone generated is controlled by the hypothalamic–
pituitary–testicular axis; as when its amount decreases, the hypotha-
lamus releases gonadotropin‐releasing hormone and this hormone
stimulates the pituitary gland to release LH and FSH. It is
noteworthy, that the two hormones of LH and FSH stimulate the
testicular tissue to generate testosterone (Planas et al., 2016).
The Leydig cells have a lower radiosensitivity compared with the
seminiferous epitheliums, and hence cancer treatments by radiation
rarely cause clinical hypogonadism (Sklar, 1999).
The findings of the current study demonstrated that the male sex
hormone levels of LH and FSH following prostate radiotherapy
significantly increase in serum level (Grigsby & Perez, 1986; Kitahara
et al., 2014; Planas et al., 2016; Tomic et al., 1983). Furthermore, it was
reported that the dose values less than 20 cGy have no effect on FSH
secretion, whereas higher dose values lead to a temporary FSH increase
(Sedlmayer et al., 1999). In addition, it was shown that LH levels
increase after 75 cGy (Rowley et al., 1974). However, there were sparse
data on testosterone levels following prostate radiotherapy, which may
be due to different scattered dose value to testes. Ishiyama et al. (2012)
reported that there is a relatively weak correlation between dose
absorbed by the testes and ratio of posttreatment to pretreatment
testosterone level. The results presented in Table 1 demonstrates that
60% of studies reveal that prostate radiotherapy can lead to a
significant decrease in testosterone levels.
4.3 | Effects of prostate radiotherapy on quality of
sex life
Although survival of patients with prostate cancer is good, their
quality of life outcome is impaired by the adverse side effects of
treatment modalities, and these negative effects vary by treatment
modalities (Lehto et al., 2017). In a study by Lehto et al. (2017), which
was performed on a large population with 523 patients, the negative
effect resulting from prostate EBRT on quality of sex life was
explained in details. In another study, Oermann et al. (2011) reported
that the sex life of patient following the prostate radiotherapy does
not significantly vary by 1 year after treatment. In the other hand, ED
as an adverse effect resulting from prostate EBRT has been reported
by several studies (Kerns et al., 2010; van der Wielen et al., 2007).
Signiﬁcantly, there is a correlation between this negative effect
induced by radiation and lower satisfaction with sexual life (van der
Wielen et al., 2007).
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4.4 | Effects of prostate radiotherapy on
testicular size
Testicular atrophy following prostate radiotherapy has been
reported by Daniell (1998) and Daniell & Tam (1998). Among the
characteristic of testicular atrophy are loss of seminiferous tubular
epithelium, thickening of the tubular basement membrane, reduction
of spermatogenesis, relative numbers of Sertoli cells located in the
seminiferous tubular epithelium, and amount of tubular and
peritubular ﬁbrosis (Andres, Bierman, & Hazzard, 1985; Robbins,
Cotran, & Kumar, 1984).
According to studies performed by Daniell’ and group, the
frequency of testicular atrophy in patients with prior prostate
radiotherapy was 2.5 times higher than that in the patients without
prior radiotherapy. Moreover, testicular atrophy, as an adverse side
effect of prostate radiotherapy, can be associated with poor
prognosis (Daniell, 1998; Daniell & Tam, 1998).
5 | CONCLUSION
Although radiotherapy is a standard treatment modality for patients
with prostate cancer, the scattered testicular dose values can lead to
testicular atrophy, variation of the male sex hormones (LH, FSH, and
testosterone) and quality of sex life. These scattered dose values and
their associated toxicities can vary by several factors such as
treatment technique used, the distance between the testicular
tissues and lower border of treatment field, and absence/presence
of testicular shield.
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